Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Flunisolide
Drug ID BADD_D00920
Description Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Indications and Usage For the maintenance treatment of asthma as a prophylactic therapy.
Marketing Status approved; investigational
ATC Code R01AD04; R03BA03
DrugBank ID DB00180
KEGG ID D00324
MeSH ID C007734
PubChem ID 82153
TTD Drug ID D0FM2P
NDC Product Code 46439-8740; 51927-1794; 50742-317; 24208-344
UNII QK4DYS664X
Synonyms flunisolide | flunisolide anhydrous | 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone | 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20- dione | flunisolide hemihydrate | flunisolide hemihydrate, (6alpha,11beta,16alpha)-isomer | Nasarel | AeroBid | Aerospan | RS-3999 | Nasalide | flunisolide acetate | RS-1320 | RS1320 | flunisolide 21-acetate | flunisolide, (6beta,11beta,16alpha)-isomer | ratio-Flunisolide | Rhinalar | Syntaris | flunisolide HFA | flunisolide hydrofluoroalkane | Apo-Flunisolide | Inhacort
Chemical Information
Molecular Formula C24H31FO6
CAS Registry Number 3385-03-3
SMILES CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sneezing22.12.03.024--
Stomatitis07.05.06.005--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tachycardia02.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Rhinalgia22.12.03.020--Not Available
Ocular discomfort06.08.03.008--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Nasal discomfort22.12.03.012--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.007--
Malnutrition14.03.02.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Candida infection11.03.03.021--
Vulvovaginal inflammation21.14.02.014--Not Available
The 4th Page    First    Pre   4    Total 4 Pages